A recent quantitative real-time PCR (qRT-PCR) study on the CD34+ bone marrow cells collected from 37 AML patients revealed that 20% to 100% of the samples expressed 2 to 33-fold higher MYCN level than normal counterpart depending on the AML subtypes. The gene discussed is CD34; the disease is acute myeloid leukemia.